CHRS
Price
$0.77
Change
-$0.01 (-1.28%)
Updated
Jun 2, 04:13 PM (EDT)
Capitalization
90.31M
59 days until earnings call
OGEN
Price
$0.18
Change
+$0.06 (+50.00%)
Updated
Jun 2, 04:31 PM (EDT)
Capitalization
2.58M
Interact to see
Advertisement

CHRS vs OGEN

Header iconCHRS vs OGEN Comparison
Open Charts CHRS vs OGENBanner chart's image
Coherus BioSciences
Price$0.77
Change-$0.01 (-1.28%)
Volume$700
Capitalization90.31M
Oragenics
Price$0.18
Change+$0.06 (+50.00%)
Volume$14.98K
Capitalization2.58M
CHRS vs OGEN Comparison Chart
Loading...
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CHRS vs. OGEN commentary
Jun 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHRS is a Hold and OGEN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 02, 2025
Stock price -- (CHRS: $0.78 vs. OGEN: $0.12)
Brand notoriety: CHRS and OGEN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CHRS: 46% vs. OGEN: 296%
Market capitalization -- CHRS: $90.31M vs. OGEN: $2.58M
CHRS [@Biotechnology] is valued at $90.31M. OGEN’s [@Biotechnology] market capitalization is $2.58M. The market cap for tickers in the [@Biotechnology] industry ranges from $307.42B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHRS’s FA Score shows that 0 FA rating(s) are green whileOGEN’s FA Score has 0 green FA rating(s).

  • CHRS’s FA Score: 0 green, 5 red.
  • OGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, both CHRS and OGEN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHRS’s TA Score shows that 4 TA indicator(s) are bullish while OGEN’s TA Score has 4 bullish TA indicator(s).

  • CHRS’s TA Score: 4 bullish, 5 bearish.
  • OGEN’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, OGEN is a better buy in the short-term than CHRS.

Price Growth

CHRS (@Biotechnology) experienced а +3.03% price change this week, while OGEN (@Biotechnology) price change was -36.84% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.64%. For the same industry, the average monthly price growth was +3.60%, and the average quarterly price growth was +0.28%.

Reported Earning Dates

CHRS is expected to report earnings on Jul 31, 2025.

OGEN is expected to report earnings on Mar 14, 2025.

Industries' Descriptions

@Biotechnology (+6.64% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CHRS($90.3M) has a higher market cap than OGEN($2.58M). CHRS YTD gains are higher at: -43.551 vs. OGEN (-67.506). CHRS has higher annual earnings (EBITDA): 37.3M vs. OGEN (-19.94M). CHRS has more cash in the bank: 97.7M vs. OGEN (3.14M). OGEN has less debt than CHRS: OGEN (519K) vs CHRS (270M). CHRS has higher revenues than OGEN: CHRS (304M) vs OGEN (0).
CHRSOGENCHRS / OGEN
Capitalization90.3M2.58M3,504%
EBITDA37.3M-19.94M-187%
Gain YTD-43.551-67.50665%
P/E Ratio1.77N/A-
Revenue304M0-
Total Cash97.7M3.14M3,108%
Total Debt270M519K52,023%
FUNDAMENTALS RATINGS
CHRS vs OGEN: Fundamental Ratings
CHRS
OGEN
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
77
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
9297
P/E GROWTH RATING
1..100
97100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OGEN's Valuation (77) in the Biotechnology industry is in the same range as CHRS (90). This means that OGEN’s stock grew similarly to CHRS’s over the last 12 months.

OGEN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CHRS (100). This means that OGEN’s stock grew similarly to CHRS’s over the last 12 months.

OGEN's SMR Rating (99) in the Biotechnology industry is in the same range as CHRS (100). This means that OGEN’s stock grew similarly to CHRS’s over the last 12 months.

CHRS's Price Growth Rating (92) in the Biotechnology industry is in the same range as OGEN (97). This means that CHRS’s stock grew similarly to OGEN’s over the last 12 months.

CHRS's P/E Growth Rating (97) in the Biotechnology industry is in the same range as OGEN (100). This means that CHRS’s stock grew similarly to OGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CHRSOGEN
RSI
ODDS (%)
N/A
Bullish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
85%
Bullish Trend 4 days ago
90%
Momentum
ODDS (%)
Bullish Trend 4 days ago
67%
Bearish Trend 4 days ago
87%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
73%
Bearish Trend 4 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
90%
Advances
ODDS (%)
Bullish Trend 5 days ago
71%
Bullish Trend 21 days ago
81%
Declines
ODDS (%)
Bearish Trend 18 days ago
87%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
89%
Aroon
ODDS (%)
Bearish Trend 4 days ago
90%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IMAB1.310.05
+3.97%
I-MAB
BBLG0.880.03
+3.58%
Bone Biologics Corp
TFX122.27-0.26
-0.21%
Teleflex
AGYS105.91-0.46
-0.43%
Agilysys
IRMD57.88-0.26
-0.45%
iRadimed Corp

CHRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CHRS has been loosely correlated with XENE. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if CHRS jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHRS
1D Price
Change %
CHRS100%
-2.87%
XENE - CHRS
41%
Loosely correlated
-0.65%
ADCT - CHRS
39%
Loosely correlated
+11.55%
ARRY - CHRS
39%
Loosely correlated
-0.30%
AXON - CHRS
38%
Loosely correlated
+2.75%
AMRN - CHRS
35%
Loosely correlated
-0.77%
More

OGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, OGEN has been loosely correlated with ATHA. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if OGEN jumps, then ATHA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OGEN
1D Price
Change %
OGEN100%
-9.37%
ATHA - OGEN
44%
Loosely correlated
+10.54%
SRPT - OGEN
30%
Poorly correlated
-2.62%
CHRS - OGEN
27%
Poorly correlated
-2.87%
RNA - OGEN
26%
Poorly correlated
-2.27%
FBRX - OGEN
25%
Poorly correlated
+1.43%
More